感染区域腹股沟下旁路术中应用冷冻保存同种异体移植物与频繁再干预和较差的无截肢生存相关
该回顾性机构描述性分析纳入2012至2015年24例因肢体缺血伴活动性感染征象行腹股沟下血运重建的患者,均使用冷冻保存同种异体移植物(CH)。30天死亡率和主要不良心血管事件均为4%,30天再干预率38%,1年主要通畅率和无截肢生存(AFS)分别为50%和58%。作者认为CH在感染且无自体静脉可选时仍为边缘性补救移植物,应仅在高度选择的患者中个体化使用。
要点
- 感染区域腹股沟下旁路术中,CH术后30天再干预率38%,再干预主要原因为清创(43%)和出血(29%)。
- 1年主要通畅率和AFS分别为50%和58%,2年分别为38%和52%。
- 随访期间63%患者需再干预,其中40%接受多次手术。
核心结论
- CH在感染且无自体静脉可选时仍为边缘性补救移植物,临床医生应仅在高度选择的患者中个体化使用这一高成本产品。
研究设计与样本
- 回顾性机构描述性分析,纳入2012至2015年因肢体缺血伴活动性感染征象行腹股沟下血运重建的24例患者(24次手术)。
主要发现
- 队列平均年龄62.5±14.4岁,平均血管外科学会风险评分3.9,就诊时基线Rutherford慢性缺血评分4.3。
- 急诊手术占29%,其余为紧急手术;除1例外CH旁路均为再次手术。
- 培养阳性率75%,最常见分离菌为金黄色葡萄球菌(29%)。
- 30天死亡率和主要不良心血管事件均为4%;30天AFS为75%,30天再干预率38%,再干预指征为清创(43%)和出血(29%)。
- 平均随访27.9±20.4个月(范围0.5-60.4),平均住院日14.8天;需额外手术或独立抗生素方案的再感染率为13%。
临床怎么用
- 作者认为CH在感染且无自体静脉可选时仍为边缘性补救移植物,临床医生应仅在高度选择的患者中个体化使用这一高成本产品。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-length saphenous vein continues to be the conduit of choice in infected-field critical limb ischemia. However, half of these individuals have inadequate vein secondary to previous use or chronic venous disease. We reviewed our outcomes of infected-field infrainguinal bypasses performed with cryopreserved homografts (CHs), a widely accepted alternative to autogenous vein in this setting. METHODS: This is a retrospective, institutional descriptive analysis of infected-field infrainguinal revascularizations between 2012 and 2015. RESULTS: Twenty-four operations were performed in the same number of patients for limb ischemia with signs of active infection. The mean age of the cohort examined was 62.5 ± 14.4 (standard deviation) years. Mean Society of Vascular Surgery risk score was 3.9 with a baseline Rutherford's chronic ischemia score of 4.3 at presentation. Emergent procedures constituted 29% of cases, and the remainder cases were urgent procedures. The CH bypass captured was a reoperative procedure in all but one of the patients. Culture positivity was present in 75% of cases with Staphylococcus aureus (29%), the most commonly isolated organism. Thirty-day mortality and major adverse cardiovascular events were both 4%. Amputation-free survival (AFS) was 75% at 30 days. Similarly, 30-day reintervention was 38% with debridement (43%) and bleeding (29%), the most common indications. Average duration of follow-up was 27.9 ± 20.4 months (range: 0.5-60.4). Mean length of stay was 14.8 days. Reinfection requiring an additional procedure or antibiotic regimen separate from the index antibiotic course was 13%. Primary patency and AFS at 1 year was 50% and 58%, respectively. Primary patency and AFS at 2 years was 38% and 52%, respectively. Limb salvage at 1 and 2 years was 70% and 65%, respectively. Fifteen patients (63%) required reintervention during the follow-up period with 40% of those subjects undergoing multiple procedures. CONCLUSIONS: CHs remain a marginal salvage conduit in the setting of infection and no autogenous choices. Therefore, clinicians should individualize usage of this high-cost product in highly selected patients only.
引用
- Wang SK, Gutwein AR, Drucker NA, et al. Cryopreserved Homografts in Infected Infrainguinal Fields Are Associated with Frequent Reinterventions and Poor Amputation-Free Survival. Ann Vasc Surg. 2018. PMID: 29421428. doi:10.1016/j.avsg.2017.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。